Marshall Islands

Medicines and pharmacy oversight in the Republic of the Marshall Islands is administered through the national health system and professional licensing framework. The official Parliament text of the Health Professional Licensing Act 2009 establishes the Board of Health Professions and the legal framework for licensed health and pharmacy practice. The publicly accessible legislation reviewed does not identify a dedicated national Good Pharmacovigilance Practice framework for marketing authorisation Holders comparable to EU GVP and does not clearly establish a Marshall Islands-resident QPPV, PSMF, universal numerical MAH ICSR reporting timelines, scheduled PSUR/PBRER submissions, a standardized RMP requirement, or a pharmacovigilance-inspection cycle. These requirements should therefore not be imported from United States, EU or other foreign pharmacovigilance systems merely because external regulatory standards may be relevant to particular supplied products. For medicines intended for the Marshall Islands, post-market safety-reporting responsibilities and any product-specific conditions should be confirmed with the competent national health authority and reflected in supply and authorisation arrangements. BAUPHARMA supporting resources (operational context only, not national regulatory evidence): Effective Signal Management in Pharmacovigilance.